Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor κB by inhibiting the inhibitor of κB kinase

Molecular Pharmacology

Volumn 64, Issue 1, 2003, Pages 123-131

  Liang, Mei Chih ^a   Bardhan, Sujata ^a,b   Li, Chaomin ^a,b   Pace, Emily A ^a   Porco Jr , John A ^a,b   Gilmore, Thomas D ^a,b  

^a USA   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DNA; ENZYME INHIBITOR; EPOXIDE; EPOXYQUINOID; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOTORREYANIC ACID; JESTERONE; JESTERONE DIMER; NATURAL PRODUCT; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER; CELL GROWTH; CHRONIC DISEASE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DIAGNOSTIC VALUE; DNA BINDING; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBUNIT; FUNGUS; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; INHIBITION KINETICS; LYMPHOMA CELL LINE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; REGULATORY MECHANISM; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

3T3 CELLS; ALKENES; ANIMALS; APOPTOSIS; DIMERIZATION; DNA, NEOPLASM; DRUG INTERACTIONS; EPOXY COMPOUNDS; HELA CELLS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; MICE; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038237037     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.1.123     Document Type: Article

References (35)

1. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, et al. (1997) Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Investig 100:2961-2969.
2. Barkett M, Dooher JE, Lemonnier L, Simmons L, Scarpati JN, Wang Y, and Gilmore TD (2001) Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3. Biochim Biophys Acta 1526:25-36.
3. Barkett M and Gilmore TD (1999) Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18:6910-6924.
4. Bremner P and Heinrich M (2002) Natural products as targeted modulators of the nuclear factor-κB pathway. J Pharm Pharmacol 54:453-472.
5. Brown K, Gerstberger S, Carlson L, Franzoso G, and Siebenlist U (1995) Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science (Wash DC) 267:1485-1488.
6. Davis RE, Brown KD, Siebenlist U, and Staudt LM (2001) Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874.
7. Epinat J-C and Gilmore TD (1999) Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene 18:6896-6909.
8. Gehrt A, Erkel G, Anke T, and Sterner O (1998) Cycloepoxydon, 1-hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene and 1-hydroxy-2-hydroxymethyl-3-pent-1,3-dienylbenzene, new inhibitors of eukaryotic signal transduction. J Antibiot (Tokyo) 51:455-463.
9. Ghosh S and Karin M (2002) Missing pieces in the NF-κB puzzle. Cell 109:S81-S96.
10. Gilmore TD, Cormier C, Jean-Jacques J, and Gapuzan M-E (2001) Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene 20:7098-7103.
11. Gilmore TD, Gapuzan M-E, Kalaitzidis D, and Starczynowski D (2002) Rel/NF-κB/ IκB signal transduction in the generation and treatment of human cancer. Cancer Lett 181:1-9.
12. Hu Y, Li C, Kulkarni BA, Strobel G, Lobkovsky E, Torczynski RM, and Porco JA Jr (2001) Exploring chemical diversity of epoxyquinoid natural products: synthesis and biological activity of (-)-jesterone and related molecules. Org Lett 3:1649-1652.
13. Ji C, Kozak KR, and Marnett LJ (2001) IκB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J Biol Chem 276:18223-18228.
14. Kakeya H, Onose R, Koshino H, Yoshida A, Kobayashi K, Kageyama S-I, and Osada H (2002) Epoxyquinol A, a highly functionalized pentaketide dimer with antiangiogenic activity isolated from fungal metabolites. J Am Chem Soc 124:3496-3497.
15. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, and Karin M (2000) Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem 275:36062-36066.
16. Kwok BHB, Koh B, Ndubuisi MI, Elofsson M, and Crews CM (2001) The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem Biol 8:759-766.
17. 1. J Pharmacol Exp Ther 296:364-371.
18. Li C, Bardhan S, Pace EA, Liang M-C, Gilmore TD, and Porco JA Jr (2002) Angiogenesis inhibitor epoxyquinol A: total synthesis and inhibition of transcription factor NF-κB. Org Lett 4:3267-3270.
19. Li C, Lobkovsky E, and Porco JA Jr (2000) Total synthesis of (±)-torreyanic acid. J Am Chem Soc 122:10484-10485.
20. Li C, Pace EA, Liang M-C, Lobkovsky E, Gilmore TD, and Porco JA Jr (2001a) Total synthesis of the NF-κB inhibitor (-)-cycloepoxydon: utilization of tartrate-mediated nucleophilic epoxidation. J Am Chem Soc 123:11308-11309.
21. Li XH, Fang X, and Gaynor RB (2001b) Role of IKKγ/NEMO in assembly of the IκB kinase complex. J Biol Chem 276:4494-4500.
22. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S-I, Inoue J-I, and Umezawa K (2000) Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 10:865-869.
23. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li JW, Young DB, Barbosa M, Mann M, Manning A, et al. (1997) IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science (Wash DC) 278:860-866.
24. Niculescu-Duvaz I, Cooper RG, Stribbling SM, Heyes JA, Metcalfe JA, and Springer CJ (1999) Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Opin Mol Ther 1:480-486.
25. Ojo-Amaize EA, Kapahi P, Kakkanaiah VN, Takahashi T, Shalom-Barak T, Cottam HB, Adesomoju AA, Nchekwube EJ, Oyemade OA, Karin M, et al. (2001) Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IκB kinase. Cell Immunol 209:149-157.
26. Pasparakis M, Schmidt-Supprian M, and Rajewsky K (2002) IκB kinase signaling is essential for maintenance of mature B cells. J Exp Med 196:743-752.
27. Pahl HL (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853-6866.
28. Pearce C (1997) Biologically active fungal metabolites. Adv Appl Microbiol 44:1-80.
29. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, and Santoro MG (2000) Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature (Lond) 403:103-108.
30. Schreiber E, Matthias P, Muller MM, and Schaffner W (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17:6419.
31. van Balderen PJ (2000) Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 129:61-76.
32. Wipf P, Hopkins TD, Jung J-K, Rodriguez S, Birmingham A, Southwick EC, Lazo JS, and Powis G (2001a) New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead. Bioorg Med Chem Lett 11:2637-2641.
33. Wipf P, Jeger P, and Kim Y (1998) Thiophilic ring-opening and rearrangement reactions of epoxyketone natural products. Bioorg Med Chem Lett 8:351-356.
34. 1 and related naphthoquinone spiroketals. Tetrahedron 57:283-296.
35. Yamamoto Y and Gaynor RB (2001) Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Investig 107:135-142.